Company intelligence / Profile preview

成都康瑞药业

Chengdu, Sichuan, China

Ownership: Private
Development stage: Other

Overview

Chengdu Kangrui New Drug Technology is a clinical-stage biopharmaceutical company based in Chengdu, China, specializing in the discovery and development of small molecule innovative drugs. The company focuses on high-value targets in immunology and oncology, utilizing its proprietary drug discovery platform to create highly selective inhibitors. Its lead candidate, KRP-101, is a potent and selective TYK2 inhibitor currently in clinical development for autoimmune conditions such as psoriasis. Kangrui Pharma aims to address unmet medical needs through precision medicine and efficient R&D processes. The company is supported by prominent investors including HighLight Capital and is located within the Chengdu Tianfu International Bio-Town.

Therapeutic areas: OncologyDermatologyImmunology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on 成都康瑞药业.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 成都康瑞药业.

Explore the full profile